Search

Your search keyword '"Ettinger, N."' showing total 93 results

Search Constraints

Start Over You searched for: Author "Ettinger, N." Remove constraint Author: "Ettinger, N."
93 results on '"Ettinger, N."'

Search Results

1. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

2. Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis

4. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

7. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

8. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

9. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

10. Edoxaban versus warfarin in patients with atrial fibrillation

11. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial

12. Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules

14. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

15. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48

16. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

17. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

18. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

19. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial

20. Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan

21. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial

22. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

23. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

39. Cytomegalovirus pneumonia: the use of ganciclovir in marrow transplant recipients.

40. Morbidity, mortality, and early results of single versus bilateral lung transplantation for emphysema

41. Pentamidine aerosol versus trimethoprim-sulfamethoxazole for Pneumocystic carinii in acquired immunodeficiency syndrome

43. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.

44. Outcomes Using a Postoperative Protocol in Pediatric Single-Stage Laryngotracheal Reconstruction.

45. Rapid-Cycle Community Assessment of Health-Related Social Needs of Children and Families During Coronavirus Disease 2019.

46. A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis.

47. "Will you treat me? I'm suicidal!" The effect of patient gender, suicidal severity, and therapist characteristics on the therapist's likelihood to treat a hypothetical suicidal patient.

48. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.

50. LRRC8A channels support TNFα-induced superoxide production by Nox1 which is required for receptor endocytosis.

Catalog

Books, media, physical & digital resources